Sunshine Biopharma Stock (NASDAQ:SBFM)
Previous Close
$2.82
52W Range
$2.42 - $640.00
50D Avg
$2.97
200D Avg
$78.09
Market Cap
$5.68M
Avg Vol (3M)
$177.90K
Beta
-1.10
Div Yield
-
SBFM Company Profile
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
SBFM Performance
Peer Comparison
Ticker | Company |
---|---|
SNOA | Sonoma Pharmaceuticals, Inc. |
TKNO | Alpha Teknova, Inc. |
LFCR | Lifecore Biomedical, Inc. |
PAHC | Phibro Animal Health Corporation |
GHSI | Guardion Health Sciences, Inc. |
ALIM | Alimera Sciences, Inc. |
SHPH | Shuttle Pharmaceuticals Holdings, Inc. |
SSIC | Silver Spike Investment Corp. |
DERM | Journey Medical Corporation |
PTPI | Petros Pharmaceuticals, Inc. |
SXTC | China SXT Pharmaceuticals, Inc. |
EGRX | Eagle Pharmaceuticals, Inc. |